The National Institute for Health and Care Excellence has appointed Adrian Hayter, a GP and former NHS England national clinical director, as its new chief medical officer. He will take up the post in June, bringing with him a career that has moved between frontline general practice and senior national roles in a way that is relatively unusual at that level.

Hayter chaired Windsor, Ascot and Maidenhead Clinical Commissioning Group between 2013 and 2018. He was then appointed in 2019 as the first GP to hold a national clinical director post at NHS England, with responsibility for older people and person-centred care. That role spanned the Covid pandemic, and he remained in post until late 2023. He joins NICE from the Royal College of General Practitioners, where he is medical director for clinical policy. He also remains a partner at Runnymede Medical Practice and will mark 30 years as a GP partner there next year. The fact that he has continued in practice throughout his national roles is notable, and it is reasonable to expect that it will shape how he approaches the job.

His appointment follows that of Jonathan Benger as NICE chief executive earlier this year. Benger described Hayter’s profile as making him well placed to support the institute’s changing role, pointing specifically to the combination of clinical practice and national leadership experience. That framing reflects something real about what NICE needs at this moment. The institute is being asked to do more, and to do it faster, and the credibility of its clinical leadership matters to how that is received by the NHS.

Hayter has said his ambition is to drive innovation into the hands of clinicians and commissioners, delivering genuine improvements in health outcomes while making responsible use of NHS resources. It is a straightforward statement of intent, but the operational challenge behind it is considerable. Getting new treatments and technologies adopted consistently across a fragmented health system has proved persistently difficult, and NICE’s recommendations have not always translated into practice at the speed the institute would want.

The appointment comes at a point of genuine expansion for NICE. This month the institute extends its technology appraisal process to require the NHS to fund approved high-impact health technologies that meet its most pressing needs. Separately, a new joint process with the medicines regulator is designed to cut the time between a drug receiving approval and reaching patients by up to six months. Both changes represent a more assertive posture from NICE, moving from guidance and recommendation toward something closer to direct influence over what the NHS adopts and when.

Whether that shift is welcomed across the health service will depend partly on how it is implemented, and partly on how well NICE communicates the reasoning behind its decisions. That is where a chief medical officer with genuine clinical credibility can make a difference. Commissioners and clinicians are more likely to engage seriously with guidance when they believe the people producing it understand what practice actually looks like.

Hayter steps into a role that carries more weight than it might have done even two or three years ago. NICE is not simply an advisory body any longer. Under the 10-Year Health Plan, it has been given a more active part to play in how innovation moves through the system. The institute’s clinical leadership will need to be visible, credible, and willing to engage directly with the parts of the NHS that are sceptical about centrally driven change. Hayter’s background suggests he understands that world. Whether he can shift the dial is another question.

‍